Sanofi $SNY Stake Increased by Keudell Morrison Wealth Management

Keudell Morrison Wealth Management increased its stake in Sanofi (NASDAQ:SNY) by 2.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,457 shares of the company’s stock after buying an additional 268 shares during the period. Keudell Morrison Wealth Management’s holdings in Sanofi were worth $650,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Nuveen LLC bought a new position in shares of Sanofi in the 1st quarter worth about $177,831,000. Federated Hermes Inc. lifted its position in shares of Sanofi by 58.5% in the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock worth $218,933,000 after buying an additional 1,456,269 shares during the last quarter. OLD Mission Capital LLC bought a new position in shares of Sanofi in the 1st quarter worth about $48,938,000. Raymond James Financial Inc. lifted its position in shares of Sanofi by 15.1% in the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock worth $179,914,000 after buying an additional 425,597 shares during the last quarter. Finally, LPL Financial LLC lifted its position in shares of Sanofi by 18.4% in the 1st quarter. LPL Financial LLC now owns 1,520,721 shares of the company’s stock worth $84,339,000 after buying an additional 236,625 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

SNY stock opened at $50.90 on Friday. The company has a market capitalization of $124.99 billion, a P/E ratio of 12.24, a PEG ratio of 1.21 and a beta of 0.51. The company has a 50-day simple moving average of $48.19 and a 200 day simple moving average of $50.03. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.73 EPS. Sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SNY. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Saturday, September 27th. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Barclays reissued an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Finally, Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $56.00 to $58.00 in a report on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.